TCR2 Therapeutics Inc
F:2K7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
RR Donnelley & Sons Co
F:DLLN
|
US |
|
A
|
ANHUI HONGYU WUZHOU Medical Manufacturer Co Ltd
SZSE:301234
|
CN |
TCR2 Therapeutics Inc
Operating Income
TCR2 Therapeutics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TCR2 Therapeutics Inc
F:2K7
|
Operating Income
-$122.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-56%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$20.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$11.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$16.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$3.9B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
12%
|
|
TCR2 Therapeutics Inc
Glance View
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm is conducting Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510, GPC3 and IL-15, which focuses on solid tumors, and CD70, which focuses on renal cell carcinoma. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor.
See Also
What is TCR2 Therapeutics Inc's Operating Income?
Operating Income
-122.9m
USD
Based on the financial report for Dec 31, 2022, TCR2 Therapeutics Inc's Operating Income amounts to -122.9m USD.
What is TCR2 Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-56%
Over the last year, the Operating Income growth was -28%. The average annual Operating Income growth rates for TCR2 Therapeutics Inc have been -34% over the past three years , -56% over the past five years .
